Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination

NEW YORK and SOUTH SAN FRANCISCO, Calif., June 2, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, Calif., today announced the postponement of BAC's extraordinary general meeting of shareholders (the "Extraordinary Meeting") originally scheduled to be held on June 3, 2022. The Extraordinary Meeting has been postponed until a to-be determined later date. Once the new date of the Extraordinary Meeting has been determined, a notice setting forth the date, time and location for the Extraordinary Meeting will be distributed to the shareholders of BAC.